Clinical-stage biopharmaceutical company GRI Bio Inc. (GRI) is under the spotlight ahead of a key clinical milestone, the release of topline data from its fully enrolled Phase 2a trial evaluating GRI-0621 for idiopathic pulmonary fibrosis or IPF. This data, expected in the third quarter of 2025, will offer a more complete picture of the drug's safety, biomarker impact, and potential efficacy over the full 12-week treatment period.
The anticipation follows the release of encouraging interim data from its ongoing Phase 2a clinical trial of GRI-0621.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.